Navigation Links
PreMD Reports Further Positive Meetings with the FDA
Date:6/13/2008

Will work together over next 60 days to try to resolve remaining issues

TORONTO, June 13 /PRNewswire-FirstCall/ - Predictive medicine company PreMD Inc. (TSX: PMD; Amex: PME) today announced that the Company has had further meetings with the U.S. Food and Drug Administration (FDA) in an effort to resolve the outstanding issues associated with obtaining broader regulatory clearance for its non-invasive skin cholesterol test. Over the next 60 days PreMD and the FDA will work together to try to obtain consensus on certain conclusions from the existing clinical data in order to develop appropriate labeling for the product.

"The FDA has provided constructive comments and assistance in defining the most appropriate strategy for clearance, and we look forward to a productive outcome at the end of the 60 days," said Brent Norton, president and CEO of PreMD.

About PreMD Inc.

PreMD Inc. is a leader in predictive medicine, dedicated to developing rapid, non-invasive tests for the early detection of life-threatening diseases. PreMD's cardiovascular products include a line of non-invasive skin cholesterol tests. PreMD's other skin cholesterol products include PREVU(x) LT, a skin cholesterol test designed for use in the life insurance industry. The Company's cancer tests include ColorectAlert(TM), LungAlert(TM) and a breast cancer test. PreMD's head office is located in Toronto, Ontario and its research and product development facility is at McMaster University in Hamilton, Ontario. For more information about PreMD, please visit http://www.premdinc.com.

This press release contains forward-looking statements. These statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the successful development or marketing of the Company's products, the competitiveness of the Company's products if successfully commercialized, the lack of operating profit and availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, product liability, reliance on third-party manufacturers, the ability of the Company to take advantage of business opportunities, uncertainties related to the regulatory process, and general changes in economic conditions. In addition, while the Company routinely obtains patents for its products and technology, the protection offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates.

Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. PreMD is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.


'/>"/>
SOURCE PreMD Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. PreMD Appeals American Stock Exchange Delisting Notification
2. PreMD Reports First Quarter Results
3. PreMD Provides Update on FDA Review
4. PreMD Reports Fiscal 2007 Results
5. PreMD Inc. Completes Debenture Financing
6. PreMD Inc. Signs Agreement with Cosmetics Conglomerate
7. PreMD Inc. Announces Debenture Financing
8. PreMD Initiates FDA Review Process and Provides Corporate Update
9. PreMD Announces FDA Decision on POC Skin Cholesterol Test
10. PreMD Announces Valuable Data on PREVU(x) LT Life Insurance Product
11. PreMD Inc. Provides Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... , ... August 18, 2017 ... ... Quick International, LLC (“Quick”), a highly specialized asset-light logistics provider of complex ... into a definitive agreement to purchase Unitrans International Corporation, a division of ...
(Date:8/18/2017)... ... August 18, 2017 , ... As an industry ... educational webinar, they will present the line of epMotion automated liquid handling system. ... you can automate everyday pipetting tasks. , Ideal for scientists and lab technicians ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... planning services to communities in east Texas, is launching a regional charity effort ... , Founded in 1991, the Pediatric Brain Tumor Foundation (PBTF) has raised nearly ...
(Date:8/18/2017)... ... ... The Golseth Agency, a Texas based insurance management and financial planning assistance provider ... organized to provide support to Christina Upchurch and her two children after the loss ... returned from out of town to find her husband passed away and their home ...
(Date:8/18/2017)... ... August 18, 2017 , ... Alcovit, a lime-flavored beverage that rids ... marketing efforts with its product now available through Jet.com. , After 25 years ... effervescent powdered drink is designed to quickly detox the body thereby avoiding alcohol-induced hangovers. ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... 2017  Axium Pharmaceuticals Inc., the creator of the drug Truveta ... beginning stages of an IPO. The United States ... average cost of a prescription epilepsy drug being $450.00-$1200.00 for a one ... AXIUM PHARMACEUTICALS, INC ... Another staggering figure is the fact that Americans spent $42 billion ...
(Date:8/14/2017)... N.J. and PETACH TIKVAH, Israel ... Inc. (NASDAQ: BCLI), a leading developer of adult stem ... the second quarter ending June 30, 2017. ... stages of preparing for our pivotal Phase 3 trial ... Chaim Lebovits , President and Chief Executive Officer of ...
(Date:8/8/2017)... Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), ... today reports its financial results for the second quarter ... during the second quarter 2017 and to date: ... clinical development programs for the Company,s lead project, BL-8040: ... pivotal study with BL-8040 as novel stem cell mobilization ...
Breaking Medicine Technology: